Home » Topics » BioWorld Science

BioWorld Science
RSS

Merck & Co. synthesizes new IDO1 inhibitors

Sep. 14, 2018

Hanyang University presents new MAPK 10 inhibitors

Sep. 14, 2018

GSK begins first-in-human study of GSK-3439171A

Sep. 14, 2018

Arrowhead Pharmaceuticals patents RNAi for thromboembolic disorders

Sep. 14, 2018

Biogen begins clinical evaluation of BIIB-078 in C9ORF72-associated ALS

Sep. 14, 2018

Natera enters agreement with Bristol-Myers Squibb for use of Signatera ctDNA assay in Opdivo trial

Sep. 14, 2018

TD-1473 being evaluated in phase II study in patients with active Crohn's disease

Sep. 14, 2018

Patient recruitment ongoing in phase I study of INCAGN-02390

Sep. 14, 2018

FDA approves Lumoxiti for relapsed or refractory hairy cell leukemia

Sep. 14, 2018

Merck & Co. evaluating MK-1654 in phase I/II study in healthy preterm and full-term infants

Sep. 14, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...